Source: Virtual Congress 2020 – Clinical and basic pharmacology for COPD
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
L. Calzetta (Rome, Italy), B. Ritondo (Rome, Italy), E. Puxeddu (Rome, Italy), M. Matera (Naples, Italy), P. Rogliani (Rome, Italy). Effect of ICS/LABA combination in an ex vivo model of COPD exacerbation. 191

Member's Comments

No comment yet.

Related content which might interest you: Beclomethasone, formoterol and glycopyrronium: synergy of dual and triple combinations in an ex vivo model of COPD exacerbation Source: Virtual Congress 2021 – Pharmacology of airway diseases: clinical and laboratory studies Year: 2021 Beclomethasone, formoterol and glycopyrronium: effect on an ex vivo model of COPD exacerbation Source: Virtual Congress 2020 – Scientific advances in airway pharmacology Year: 2020 Effect of ICS withdrawal on COPD exacerbations in patients on triple therapy at baseline Source: International Congress 2018 – COPD management Year: 2018 Pharmacological characterization of the protective effect of mepolizumab against airway hyperresponsiveness in a human ex vivo model of severe asthma Source: International Congress 2019 – Advances in asthma pharmacology Year: 2019 Comparative effectiveness of two different doses of inhaled corticosteroid in triple therapy on exacerbations in patients with severe COPD: a real-world study Source: Virtual Congress 2021 – Therapies for respiratory diseases in primary care and COVID - 19 Year: 2021 Does the choice of ICS/LABA regimen influence exacerbation rates in asthma patients with high as-needed use? Source: Annual Congress 2007 - Recent advances in our understanding of the treatment of asthma Year: 2007 Effects of add-on treatment with budesonide/formoterol combination in eosinophilic COPD patients Source: International Congress 2017 – Management of COPD Year: 2017 Efficacy of a combination therapy with single inhaler budesonide/formoterol in the treatment of acute exacerbations of COPD (AECOPD) Source: Eur Respir J 2004; 24: Suppl. 48, 252s Year: 2004 Effects of a single inhaled budesonide/formoterol dose on glucocorticoid receptor activity in sputum of COPD patients Source: International Congress 2016 – Novel insights into the treatment of COPD Year: 2016 Intermittent treatment with budesonide/formoterol in an allergic rat model Source: Eur Respir J 2005; 26: Suppl. 49, 123s Year: 2005 Effects of budesonide/formoterol combination therapy versus budesonide on airway dimensions in asthma Source: Annual Congress 2012 - Clinical aspects and treatment of asthma and allergic respiratory diseases Year: 2012 Pharmacological characterization of the anti-oxidant activity of N-acetylcysteine in an ex vivo model of COPD exacerbation Source: International Congress 2016 – Airway pharmacology: drug targets and mode of action Year: 2016 The lung microbiota changes associated with inhaled corticosteroid and azithromycin in murine model of COPD Source: International Congress 2018 – Identification of therapeutic targets for asthma Year: 2018 Effect of dupilumab on oral corticosteroid use in severe asthma patients with improving lung function Source: Virtual Congress 2020 – Recent innovations regarding the mechanisms and treatments of asthma Year: 2020 Reducing the dose of inhaled corticosteroids (ICS) under therapy with montelukast in stable asthma: effects on lung function and inflammation Source: Eur Respir J 2001; 18: Suppl. 33, 261s Year: 2001 Efficacy of roflumilast in the frequent exacerbation COPD phenotype Source: Annual Congress 2011 - Biomarkers and exacerbations of asthma and COPD Year: 2011 Preclinical in vivo assessment of ciclesonide, a novel corticosteroid for the treatment of asthma Source: Eur Respir J 2001; 18: Suppl. 33, 95s Year: 2001 Effect of roflumilast on exacerbations in patients with severe COPD and a prior history of hospitalization taking combination therapy Source: International Congress 2015 – Advances in the future treatment of COPD Year: 2015 Pharmacological characterization of the protective effect of benralizumab against airway hyperresponsiveness in a human ex vivo model of severe asthma Source: International Congress 2019 – Advances in asthma pharmacology Year: 2019 The role of nebulised budesonide in the treatment of acute exacerbations of COPD Source: Eur Respir J 2007; 30: 399-400 Year: 2007